Enterprise Value

1.213B

Cash

1.261B

Avg Qtr Burn

-86.95M

Short % of Float

15.40%

Insider Ownership

2.56%

Institutional Own.

97.27%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Vepdegestrant (ARV-471)(oral ER-targeting PROTAC® protein degrader) Details
Breast cancer, Cancer, Solid tumor/s

Big Mover™

Susp. Mover™

Phase 3

Data readout

Vepdegestrant (ARV-471) Details
Cancer, Breast cancer, Solid tumor/s

Phase 2

Data readout

ARV-766 +/- abiraterone Details
Castration-resistant prostate cancer, Prostate cancer, Cancer, Solid tumor/s

Phase 1/2

Data readout

Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details
Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s

Phase 1/2

Update

Phase 1/2

Update

Phase 1/2

Update

Phase 1

Data readout

Vepdegestrant (ARV-471) Details
Cancer, Breast cancer, Solid tumor/s

Phase 1

Data readout